Introduction: The long-term goal of chronic hepatitis B (CHB) treatment is improvement of
Results: At baseline, mean (standard deviation) serum hepatitis B virus (HBV) DNA load was 8.5 (1.7) log 10 copies/mL, Knodell necroinflammatory score was 7.6 (2.9), and Ishak fibrosis score was 2.2 (1.1). After antiviral treatment (median duration:
261 weeks), liver histology improved with increased proportions of patients with absence/minimal liver inflammation (Knodell necroinflammatory score B3), from 16% (9/57) at baseline to 98% (56/57), and absence/ minimal fibrosis (Ishak score B1), from 25% (14/57) at baseline to 84% (48/57). At Year 5, HBV DNA load was\300 copies/mL for all patients; cumulative HBeAg loss and seroconversion rates were 88% and 77%, respectively. At Year 6, 95% of patients with abnormal baseline glomerular filtration rate Asia-pacific region became infected with HBV during childhood, and 5-10% of the adult population is chronically infected. It is estimated that about 600,000 deaths occur each year due to acute or chronic hepatitis B (CHB) [1] .
Between 15% and 20% of patients with chronic HBV replication will develop cirrhosis within 5 years [2, 3] . The REVEAL study demonstrated that progression to cirrhosis in hepatitis B-infected persons is strongly correlated with levels of HBV replication and serum HBV DNA level, with a DNA load C10,000 copies/mL a strong risk predictor of hepatocellular carcinoma [4, 5] . Moreover, increased serum HBV DNA levels also increased the mortality risk for all causes or causes related to chronic liver disease [6] . Several other studies have also correlated serum HBV DNA concentrations with the progression of chronic liver disease [7] [8] [9] [10] .
Viral replication is now recognized as the key driver of liver injury, and international guidelines recommend that permanent suppression of HBV replication is the primary aim of CHB treatment [1, 11, 12] . The ultimate goal of antiviral therapy is to improve survival by preventing liver disease progression to cirrhosis, liver failure, and hepatocellular carcinoma [12] .
previously considered irreversible, recent studies indicate that profound and durable viral suppression is associated with the regression of liver fibrosis, which improves clinical outcomes in patients with CHB or chronic hepatitis C [14] [15] [16] .
Telbivudine provides effective treatment in CHB patients, as shown in randomized, double blind, multicenter phase 3 trials. The 2-year GLOBE study demonstrated the superiority of telbivudine 600 mg/day over lamivudine 100 mg/day with greater HBV DNA suppression and less genotypic resistance [17, 18] . Study 015, with a similar design to the GLOBE study, was conducted entirely in China and also showed greater antiviral and clinical efficacy responses for telbivudine, with less resistance, when compared with lamivudine after 2 years of treatment [19] .
Telbivudine-treated hepatitis B e antigen (HBeAg)-positive patients achieved a higher cumulative seroconversion rate, suggesting long-lasting benefits of telbivudine treatment [20] .
Long-term treatment with oral antiviral agents, such as lamivudine, adefovir, entecavir, and tenofovir slows the clinical and histologic progression of CHB in patients with advanced fibrosis and cirrhosis [14, [21] [22] [23] [24] [25] .
However, no information is available on liver histology after long-term treatment with telbivudine. This study evaluated the impact of telbivudine treatment on liver inflammation and fibrosis in CHB patients after 5 years.
METHODS

Study Design
The study cohort consisted of patients who completed 2 years of telbivudine or lamivudine treatment in the phase 3 GLOBE or 015 studies, and subsequently continued with telbivudine for an additional 4 years (study CN04E1, ClinicalTrials.gov # NCT00877149). Liver biopsies were taken at baseline in the phase 3 studies and after 5 years of antiviral treatment (Fig. 1) (GLOBE study), NCT00131742 (study 015),
NCT00142298
(study 2303), and NCT00646503 (study CN04).
Study Population
Detailed inclusion and exclusion criteria in GLOBE/015 studies have been described earlier [18, 19] 
Histologic Evaluations
Histologic evaluation of the liver biopsies was [24, 25] . To ensure a ''reference standard'', Prof. Zachary Goodman's hospital rules and guidelines on liver biopsy assessment (Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA) were followed. The protocol was established as the current practice in our hospital. Biopsies that did not match the criteria were excluded from the analysis.
Stages of fibrosis were assessed using the Ishak fibrosis score that ranges from 0 (no fibrosis) to 6 (cirrhosis; probable or definite) [26] . Changes in Ishak fibrosis score from baseline were categorized as: improvement (C1-point decrease), worsening (C1-point increase), or no change (post-baseline score = baseline score). Absence/minimal fibrosis of liver biopsy was defined as Ishak score B1; advanced fibrosis/cirrhosis was defined as Ishak score C4.
Virologic, Serologic, and Biochemical Evaluations
Serum HBV DNA quantitation was performed at a central laboratory using the COBAS Amplicor TM HBV assay (Roche Diagnostics, Pleasanton, CA, USA) that utilizes polymerase chain reaction (PCR) methods and automated sample readout technologies (limit of detection: 300 copies/mL). Other HBV serologic markers (HBsAg/anti-HBs, HBeAg/anti-HBe) using standard commercially available assays were also assessed centrally.
Serum Fibrosis Markers
Serum fibrosis markers were not assessed at baseline in the GLOBE/015 studies. These were centrally tested at baseline and Week 52 of CN04E1 study period, namely Year 5 or Year 6 of long-term antiviral treatment, using standard commercially available assays. Serum concentrations of procollagen III peptide and collagen IV were measured by radioimmunoassay (P III P RIA assay; Cis Bio
International, Gif-sur-Yvette, France) and enzyme immunoassay (Type IV collagen EIA assay; Argutus Medical, Dublin, Ireland), respectively.
Transient Elastography Measurements
Transient elastography (FibroScan) [27, 28] was used for diagnosis and overall assessment of hepatic fibrosis (by measuring liver stiffness) in a subgroup of 14 patients included in study CN04E1. No measurements at baseline or during the first 5 years of treatment were available.
Safety
The assessment of safety was based on the analysis of adverse events (AEs), including serious AEs (SAEs) and AEs of special interest: muscle weakness, myopathy or myositis, and peripheral nephropathy, laboratory evaluations, vital signs, and physical examinations.
Glomerular Filtration Rate Evaluations
Estimates of glomerular filtration rate eGFR) are the best indices of kidney function [29] [30] [31] .
eGFR is estimated using prediction equations that take into account the serum creatinine 
Statistical Analysis
The safety population consisted of all patients who received at least one dose of study drug in study CN04E1. All safety analyses were performed on the safety population throughout the whole telbivudine treatment period. The histology analysis was performed on the histology population of enrolled patients who had paired evaluable liver biopsy results at both feeder study baseline and study CN04E1 entry (or at the end of study 2303 if study CN04E1 entry biopsy was not available).
The 
RESULTS
The study population included 70 patients, of which 66 had at least one post-baseline assessment of serum HBV DNA (intent-to-treat population).
Of these, 57 patients had paired evaluable liver biopsies at both baseline and after 5 years of antiviral treatment. The baseline characteristics of these 57 patients (Table 1) were similar in disease features to those in the GLOBE study and study 015. All patients were Chinese with HBV genotype either B or C. Mean baseline HBV DNA load was 8.5 log 10 copies/mL, Knodell necroinflammatory score was 7.6, and the Ishak fibrosis score was 2.2. Six of the 57 patients (11%) had an Ishak fibrosis score C4, indicating advanced fibrosis or cirrhosis.
Thirty-three patients received telbivudine 600 mg/day for 5 years and 24 patients received lamivudine 100 mg/day for 2 years followed by telbivudine for 3 years. Median duration of treatment was 261 weeks.
Assessment of Liver Inflammation
Long-term treatment with telbivudine resulted in marked improvement of liver inflammation. Figure 2a shows microphotographs of biopsy samples from a representative patient whose Knodell score decreased from 10 (at baseline) to 1 (minimal inflammation) after long-term treatment with telbivudine. This observation was consistent among all 57 patients (Fig. 3a) .
Long-term treatment resulted in effective control of HBV replication. 
Assessment of Liver Fibrosis
Long-term telbivudine treatment resulted in reversal of liver fibrosis (Fig. 2b) . Figure 3b represents the evolution of Ishak fibrosis scores in all patients during long-term treatment. The proportion of patients with no or minimal fibrosis (defined as Ishak fibrosis score B1)
increased from 25% (14/57) at baseline to 84% (48/57) after long-term treatment (75%) ( 
Serum Liver Fibrosis Markers
The mean (SD) levels of procollagen III peptide 
Virologic and Biochemical Response
At the time of long-term biopsy, 100% (n = 66) of patients had undetectable HBV DNA as determined by PCR. The median HBV DNA level decrease was -7.6 log 10 copies/mL in HBeAg-positive patients (p\0.0001) and -5.3 log 10 copies/mL in HBeAg-negative patients (p\0.0001). The median time to maintained PCR negativity (defined as HBV DNA\300 copies/mL for at least two consecutive visits) was 168 days in HBeAg-positive patients and 116 days in HBeAg-negative patients. After 6 years (2190 days) of treatment, median duration of maintained PCR negativity was Table 2 ).
Safety Evaluations
Among the safety population, telbivudine was well tolerated over the 6-year treatment period (95.7% of patients received telbivudine for C208 weeks). Eight patients The most frequent AE of special interest was blood creatine kinase increase (11.4%; 8 patients). One patient (1.4%) experienced muscular weakness. According to the investigator's judgment, this moderately severe muscle-related AE was linked to telbivudine treatment. There were no severe AEs of special interest observed. There were no reports of myopathy, rhabdomyolysis, lactic acidosis, or pancreatitis as an AE in this study.
On-treatment ALT flares (AASLD definition) [33] were reported in 17.1% (12/70) of patients, mainly during the first 6 months of treatment.
Glomerular Filtration Rate Evaluations
GFR, assessed using the MDRD equation, increased steadily from baseline to the end of 6 years of treatment. Mean GFR increased by 60.5% at 6 years (Fig. 4) 
DISCUSSION
The present study demonstrated that prolonged telbivudine treatment effectively controls HBV replication. This results in marked improvement of liver histology, resolution of inflammation, improvement (reversal) of liver fibrosis, and extends previous findings. In the GLOBE phase 3 study, histologic response (defined as a reduction of C2 points in the Knodell necroinflammatory score) was observed in 64.7% of patients as early as Week 48 [18] .
Among patients who had marked fibrosis/cirrhosis, the Ishak fibrosis score improved (Ishak score B3) in 68% and 59% of HBeAg-negative and HBeAg-positive patients, respectively [18] .
In the present analysis, the long-term improvement on fibrosis in nucleos(t)ide-naïve CHB patients was confirmed after a median A high proportion of patients achieved HBeAg loss/seroconversion (88%/77%) [24] . Previous long-term histologic trials reported an improvement of necroinflammation and fibrosis, respectively, in 56% and 24% of patients treated with lamivudine (3 years); 67% and 60% of HBeAg-positive patients and 83% and 71-73% of HBeAg-negative patients treated with adefovir (5 years), respectively [14, 22, 23] . In a recent large-scale prospective study examining changes in liver histology during tenofovir treatment, paired biopsies from 348 patients showed that 176 (51%) patients demonstrated regression of fibrosis after 5 years of treatment [34] . The effects of telbivudine in regression of fibrosis (80-84% improvement in fibrosis) showed consistent efficacy reported with other antiviral trials.
Although these long-term histologic trials are not directly comparable, data from a 6-year entecavir trial suggested that telbivudine achieved numerically better histologic improvement, particularly in patients with high necroinflammation score at baseline: 98% and 75% of patients in telbivudine and entecavir treatment cohorts, respectively, 
